Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
- ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ...
2019-10-28 20:30
3073
Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China
Arena eligible to receive up to $224M, including upfront and milestone
payments, in addition to royalties
SAN DIEGO, Dec. 5, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
2017-12-05 21:30
4955
